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Introduction
Dear Colleagues,
Cystic Fibrosis (CF) was described for the first time
as a clinical entity in the third decade of the last century.
In 1960 the autosomal recessive inheritance of the dis-
ease was established, and it took another three decades
to clone the causative gene in 1989. Since then, the
genetics of CF have produced an enormous amount of
important data culminating in the description of more
than 1000 different mutations in the CF Transmembrane
conductance Regulator (CFTR) gene, genotype–pheno-
type correlations, many CFTR structure functions find-
ings and even first trials of gene therapy. The discovery
of the causative gene and its many mutations has
allowed an improved epidemiological description of the
disease but also revealed its complexity. Knowledge of
the structure, function and localization of the protein has
also led to a better understanding of the pathogenesis of
CF, leading to the development of new treatment strat-
egies. Besides the genetics of CF, many other areas of
CF research grew rapidly in the last century and in the
year 2000, CF created 649 direct publications with a
huge diversity of topics. These include research areas of
acute and chronic inflammation, aerosol technology,
antibiotics, apoptosis, cell biology, chaperones, clinical
and basic microbiology, cytokines, electrophysiology,
exercise and physiotherapy, defensins, diabetes, gastro-
enterology, genomics and proteomics, immunology, liver
disease, mutation analysis, mucociliary clearance, neo-
natal screening, nitric oxide, osteoporosis, transplana-
tion, vaccine development and many more.
No doubt, CF is a very complex disease! Shouldn’t
this complexity be collected and presented in one journal
which will be distributed worldwide? Wouldn’t it con-
vincingly demonstrate the multiple activities in many
countries of the world to cure one terrible disease?
The European Cystic Fibrosis Society with its mission
to facilitate the acquisition and distribution of knowledge
and to support research into all aspects of CF, was imme-
diately enthusiastic when the idea was born to create a
journal devoted to all aspects of CF. We felt extremely
lucky when we learned that Elsevier shared our enthu-
siasm. The Journal of Cystic Fibrosis, which represents
the official Journal of our Society, will serve as a plat-
form on which people from various disciplines and with
a common interest in CF can express and discuss their
latest scientific findings. An international Editorial
Board composed of well-known experts in the field of
CF will secure that the scientific level of the manuscripts
remains high. We are more than happy that Dr Harry
Heijerman has accepted to lead the Journal of Cystic
Fibrosis as Editor-in-Chief in the first important years.
Last but not least, such an ambitious effort needs finan-
cial support and we are indebted to Chiron Corporation
for their commitment to help us launching the Journal
of Cystic Fibrosis.
I have no doubts that the Journal of Cystic Fibrosis
has a splendid prognosis! You can support my vision by
submitting your next manuscript to the Journal of Cystic
Fibrosis.
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